source
- Moving NAMs from Progress to Practice: Building the Foundation for Broader AdoptionThe future of NAMs depends on more than innovation. Learn how sourcing, standards and evidence can accelerate adoption.Fierce Biotech · 5d ago↗ source
- Inhibrx’s OX40 agonist plus Keytruda shows 48% response rate, beating Keytruda alone in head and neck cancer Phase 2Inhibrx reported results from its Phase 2 HexAgon trial evaluating INBRX-106, an OX40 receptor agonist, combined with Merck’s Keytruda in patients with treatment‑naïve, PD‑L1‑positive metastatic or…